When putting together your watch list, look for stocks with an 80 or higher RS Rating. Phreesia just met that criteria with a new score of 87.
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains typically have an 80 or better RS Rating as they begin their biggest price moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to establish and enter a buying range in heavy trade.
The company posted 0% EPS growth in the latest quarterly report, while sales growth came in at 15%.
The company holds the No. 5 rank among its peers in the Computer Software-Medical industry group. Doximity is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
